Literature DB >> 32360532

Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.

Jiahao Liu1, Xiaofei Jiao1, Qinglei Gao2.   

Abstract

Neoadjuvant chemotherapy (NACT) has been regarded a standard treatment for advanced ovarian cancers for decades. Among patients who are poor candidates for primary debulking surgery (PDS), NACT is likely their only option in clinical practice. However, NACT failed to show any survival benefit in the reported randomized controlled trials (RCTs) and the meta-analyses, compared with PDS. This phenomenon raises concerns over the unfavorable influence of NACT, that is, the potential risk of inducing platinum resistance. In this review, we reveal the risk of NACT-related platinum resistance by summarizing the experimental and clinical evidence and discuss new attempts to avoid this phenomenon.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Year:  2020        PMID： 32360532     DOI： 10.1016/j.drudis.2020.04.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  9 in total

Review 1.  Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer.

Authors:  Ami Patel; Puja Iyer; Shinya Matsuzaki; Koji Matsuo; Anil K Sood; Nicole D Fleming
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

2.  Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.

Authors:  Dongchen Zhou; Jiahao Liu; Ronghua Liu; Huayi Li; Yi Huang; Ding Ma; Li Hong; Qinglei Gao
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

3.  Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.

Authors:  Yongmei Li; Yufei Nie; Hongyan Guo; Hua Guo; Chunfang Ha; Yuan Li
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

4.  Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin.

Authors:  Yin Tao; Xue-Ting Tang; Xing Li; An-Shan Wu; Hou-Shen Zhou; Cheng-Fang Zhou
Journal:  Front Med (Lausanne)       Date:  2022-03-09

Review 5.  Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer.

Authors:  Zhou Jin; Yu Chenghao; Peng Cheng
Journal:  Front Pharmacol       Date:  2022-01-25       Impact factor: 5.810

6.  The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients.

Authors:  Daying Mou; Shengyan Xie; Pingyuan Li
Journal:  Contrast Media Mol Imaging       Date:  2022-06-08       Impact factor: 3.009

7.  The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma.

Authors:  Yuanming Shen; Yan Ren; Kelie Chen; Yixuan Cen; Bo Zhang; Weiguo Lu; Junfen Xu
Journal:  Oncogenesis       Date:  2022-07-30       Impact factor: 6.524

8.  Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.

Authors:  Nicole E James; Morgan Woodman; Payton De La Cruz; Katrin Eurich; Melih Arda Ozsoy; Christoph Schorl; Linda C Hanley; Jennifer R Ribeiro
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

9.  Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.

Authors:  Aditi Bhatt; Snita Sinukumar; Vahan Kepenekian; Praveen Kammar; Sanket Mehta; Sakina Shaikh; Witold Gertych; Naoual Bakrin; Olivier Glehen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.